Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Trial Data
  5. Trial Results

Trial Results

Evaluate

July 27, 2023

Mounjaro bests Wegovy yet again

But supply problems are getting worse.

Thumbnail
July 24, 2023

Bavarian Nordic cans respiratory vaccine

Article image
Vantage logo
July 18, 2023

AAIC 2023 – Acumen’s new amyloid approach impresses

But how different is ACU193 really?

Article image
Vantage logo
July 17, 2023

AAIC 2023 – Lilly downplays tau testing needs

But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.

Article image
Vantage logo
July 17, 2023

Argenx surges after hit in nerve disorder

The Belgian group is riding high as investors look for future successes in other inflammatory diseases.

Article image
Vantage logo
July 17, 2023

Bridgebio finally gets its cardiomyopathy win

A convincing hit puts approval, and potentially partnerships, on the table.

Article image
Vantage logo
July 14, 2023

Caribou’s allogeneic Car meets a six-month bar

But relapses are still frequent – a problem that, curiously, higher dosing has not assuaged.

Article image
Vantage logo
July 14, 2023

Theseus’s Asco disappointment bites

Article image
Vantage logo
July 13, 2023

Pharma finds a way to gain weight

In the second quarter it paid to be a leading obesity company. As for Covid, not so much.

Article image
Vantage logo
July 12, 2023

Stock market strife subsides in second quarter

But large gains for some big pharma players flatter the overall figures.

Article image
Vantage logo
July 11, 2023

A chronic disappointment for Viridian

Without full placebo data, it is hard to handicap VRDN-001’s chances in thyroid eye disease.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up